Introduction
Initiation of the adaptive immune response is believed to be a result of local necrotic death of tissues and release of inflammatory cytokines by resident macrophages, mast cells and recruited polymorphonuclear leukocytes. The initial cytokines released at the site of an acute inflammatory response include IL-1, IL-6, IL-12 and IL-18, 1 as well as a number of chemokines. Tumor recognition 3 also requires induction of an immune response, recruitment and maturation of dendritic cells, 3 and IL-12 mediated expansion of T cells specific for tumor antigen. 4 IL-18 is a recently identified monokine with important immunoregulatory functions which induces high levels of IFN-␥ secretion from both NK and T cells. 5 IL-12 synergizes with IL-18 to enhance IFN-␥ production by upregulating the expression of IL-18 receptors on T cells. 6, 7 IL-18 is produced by cells of monocyte lineage, augments NK cytolytic activity and enhances proliferation of T cells. 5 We and others have reported significant antitumor effects of recombinant (r) IL-18 administration in tumorbearing mice. 8, 9 Systemic administration of rIL-18 suppressed the growth of MCA205, but complete eradication of tumor was not observed when treatment with rIL-18 was initiated on day 7 or later. Combination therapy with systemic rIL-12 and rIL-18 administration was associated with significantly enhanced antitumor effects when compared with that of rIL-12 or rIL-18 alone; however, lethal side-effects were observed concomitant with extremely high serum levels of IFN-␥. To overcome these problems, we examined the effectiveness and safety of IL-18 gene therapy employed as an alternative strategy for cancer immunotherapy.
L-18, like IL-1, lacks a typical signal sequence for cytokines. 5 It is only processed into the mature active form by Caspase-1, an IL-1␤ converting enzyme. 10, 11 In the case of IL-1␤, several reports indicate that the addition of a conventional signal sequence is necessary for extracelluar secretion of mature IL-1␤. [12] [13] [14] Therefore, we fused a signal sequence derived from human prepro-parathyroid hormone 14 to the 5′ end of mature IL-18 cDNA to construct vectors capable of expressing bioactive IL-18. In the present study, we demonstrated that direct injection of an IL-18 adenoviral vector into tumor elicited an effective immune response, as well as potent antitumor effects 
Results
Fusion of the signal sequence from human parathyroid hormone to mature murine IL-18 cDNA fragment enables the production of biologically active IL-18 MCA205 cells were transduced with retroviral vectors carrying the full length cDNA of IL-18 (MCA205 DFG.FL.IL-18.Neo) (Figure 1a ) or a cDNA of mature IL-18 fused with the prepro sequence of human parathyroid hormone (MCA205 DFG.PTH.IL-18.Neo) (Figure 1b ) (see Materials and methods). Conditioned medium was prepared from 10 6 of these transfectants, cultured for 24 h, and measured for secreted IL-18 in the medium using an ELISA. Simultaneously, to confirm that the secreted IL-18 was biologically active, an aliquot of the conditioned medium was measured for the ability of these supernatants to induce IFN-␥ from cocultured splenocytes in 24 h (Figure 2a ). (Figure 1c and 2b) . MCA205 cells transduced with Ad.PTH.IL-18 at a multiplicity of infection (MOI) of 1000 and 100 produced IL-18 (57.0 ± 1.1 and 2.9 ± 0.1 pg/10 6 cells/24 h, respectively) which can induce a significant amount of IFN-␥ (32.8 ± 0.9 and 8.0 ± 3.5 pg/10 6 cells/24 h, respectively) from splenocytes. All mice completed the full treatment cycle without apparent side-effects. Blood samples were taken from two mice in each group before and 2 days after the first injection of Ad.PTH.IL-18 and serum levels of IFN-␥ were measured by ELISA. Serum IFN-␥ levels of all samples before treatment were below limit of detection (Ͻ15.6 pg/ml). Serum IFN-␥ levels of the mice treated with systemic administration of HBSS were also lower than 15.6 pg/ml regardless of the i. 
PTH.IL-18 was associated with significant inhibition of tumor establishment (−/IL-18) and completely eradicated tumors in four of five animals. Depletion of NK cells completely abrogated the antitumor effects of Ad.PTH.IL-18 (ASGM1/IL-18). Growth of the tumor inoculated in mice treated either with anti-CD4 (CD4/HBSS) or anti-CD8 Ab (CD8/HBSS) was more rapid when compared with that of untreated mice. Treatment with anti-CD4 Ab (CD4/IL-18) or anti-CD8 Ab (CD8/IL-18) partially abrogated the growth inhibitory effects of administration of Ad.PTH.IL-18.
were the predominant cells infiltrating tumors treated with IL-18.
IL-18 gene has similarities with IL-1 genes in amino acid sequence (12% homology with IL-1␣ and 19% with IL-1␤, respectively) and lacks a typical leader sequence. by Caspase-1, the IL-1␤-converting enzyme. 10, 11, 15, 16 As a substrate IL-18 is more avidly cleaved by this enzyme than IL-1 itself. Cell lines transfected with full-length pro-IL-1␤ cDNA failed to process the IL-1␤ precursor or to secrete the mature protein. 17 Several studies demonstrated that fusion of heterologous signal peptides to the region of mature IL-1␤ cDNA allowed secretion of mature IL-1␤ from transduced cells. [12] [13] [14] Adopting this strategy, we constructed IL-18 recombinant viral vectors using the mature IL-18 cDNA ligated to the prepro leader sequence of the human parathyroid hormone gene (Figure 1b, c) and confirmed secretion of bioactive IL-18 from the cells transfected with these vectors carrying hybrid IL-18 gene (Figure 2) . We also detected secretion of bioactive IL-18 from other murine cell lines, such as colon cancer, lung cancer and melanoma cell lines following infection with Ad.PTH.IL-18 (unpublished data).
of Ad.PTH.IL-18 on day 9. Tumors were excised from mice on day 11 and examined for infiltrating cells using immunohistochemistry. Each sample was immunostained with anti-CD4 (a, b, c) or anti-CD8a (d, e, f) antibodies, respectively. The stained cells were counted in five fields at a magnification of ×400 in each sample. Nonparametric Wilcoxon rank test was used in the statistical analysis of the number of immunostained cells found in a tumor in individual groups. Representative photographs are shown with the number of the counted immunostained cells infiltrating in tumor. HBSS or
We have previously reported that significant antitumor effects of systemic administration of rIL-18 in tumor bearing mice. 9 Systemic administration of 1 g per day of rIL- Figure 3b ) suppressed the growth of an established MCA205 tumor even when treatment was initiated as late as day 9. These data suggest that limited production of IL-18 by Ad.PTH.IL-18 was enough to mediate significant antitumor effects. Intradermal injection of Ad.PTH.IL-18 into the contralateral flank at a site distant from the tumor did not have any apparent antitumor effects. Thus, it is likely that the antitumor effects of peritumoral injection with Ad.PTH.IL-18 is mediated not by the systemic circulation of IL-18, but rather by local high concentration of IL-18. Since most of the mice (four of five), which had complete regression of MCA205 cells following peritumoral injection of Ad.PTH.IL-18, rejected a subsequent challenge with tumor (Figure 3a ), it appears that such an approach can indeed induce a potent and specific systemic immune memory against tumor. Destruction of tumor cells following injection of Ad.PTH.IL-18 could cause enhanced processing and presentation of tumorassociated antigen, increased activation of antigenpresenting cells, or increased T cell responses ultimately inducing a systemic immune response.
In our previous study, 9 systemic daily administration of 1 g of rIL-18 combined with 0.1 g of rIL-12 had the most significant antitumor effects on an established MCA205 tumor, but severe toxicity and death was noted in all animals by the 4th day of treatment. Side-effects included hemorrhagic diarrhea and weight loss accompanied by extremely high levels of serum IFN-␥ (17 671.5 ± 107.1 pg/ml). To avoid these deleterious effects of combination therapy, we employed peritumoral injection of Ad.PTH.IL-18 as an alternative to systemic administration of rIL-18 and examined its antitumor and side-effects (Figure 3b ). Systemic administration of rIL-12 at suboptimal dose enhanced antitumor effects of reduced doses (3 × 10 8 p.f.u.) of peritumoral injection of Ad.PTH.IL-18 without apparent side-effects. The intradermal injection of Ad.PTH.IL-18 did not cause significant elevation of serum IFN-␥ even when combined with rIL-12. These data suggest that such an approach is not only an effective way to suppress tumor growth, but is also much safer (at least in mice) when combined with systemic administration of rIL-12.
Depletion with anti-ASGM1 Ab completely abrogated the antitumor effects of Ad.PTH.IL-18 ( Figure 4) 
Materials and methods

Construction of retroviral vector and establishment of IL-18 transfectants
The 818 bp fragment of full length murine IL-18 cDNA (supplied from Hayashibara Biochemical Institute, Okayama, Japan) was used as a template to amplify and generate an NcoI site at the initiation codon and an EcoRI site at the 3′ end of this fragment by PCR. This fragment was designated as FL.IL-18. The sense and anti-sense primer sequences used were as follows: 5′ GAGCCATGGCTG-CCATGTCAGAAGAC 3′ and 5′ GAGGAATTCAGGCG-AGGTCATCAC 3′ (amplification cycles: 30; annealing temperature: 65°C). To allow positive selection for retrovirally transfected cells, IRES-Neo fragment with an EcoRI site at the 5′ end and a BamHI site at the 3′ end was prepared as previously described. 23 FL.IL-18 and IRES-Neo fragments were ligated between the NcoI and BamHI sites of the proviral plasmid termed MFG. 24 This retroviral vector was designated as DFG.FL.IL-18.Neo (Figure 1a) . To facilitate efficient secretion of bioactive IL-18, the fragment encoding the prepro leader peptide (amino acid 1-31) of human thyroid hormone 14 was fused to the sequence encoding mature IL-18 cDNA, and this fragment was termed PTH.IL-18. The PTH.IL-18 fragment and the IRES-Neo fragment were ligated to the MFG retroviral vector plasmid and this vector was designated as DFG.PTH.IL-18.Neo (Figure 1b) . Retroviral supernatant was generated by transfecting these proviral plasmids into BING cell lines. 25 To obtain IL-18 transfectants, MCA205 (a gift from Dr SA Rosenberg, National Cancer Institute, Bethesda, MD, USA) were transduced with retroviral supernatant of DFG.FL.IL-18.Neo. and DFG.PTH.IL-18.Neo. and underwent selection with G418 as previously described.
Construction of IL-18 adenoviral vector
The PTH.IL-18 fragment was inserted into a shuttle plasmid termed pAdlox to make an E1 and E3-substituted recombinant adenoviral vector 26 and this plasmid was designated as Adlox.PTH.IL-18 ( Figure 1c) . A recombinant adenoviral vector encoding PTH.IL-18 was made through Cre-lox recombination as previously described 26 and termed Ad.PTH.IL-18. All of the necessary materials for constructing Ad.PTH.IL-18 were kind gifts from Dr Stephen Hardy (Cell Genesys, Alameda, CA, USA).
Bioassay and ELISA for cytokines Biologic activity of IL-18 produced from MCA205 transfectants was measured by their ability to induce IFN-␥ from murine splenocytes as described elsewhere. 27 Secretion of IFN-␥ and IL-18 in the culture media from the IL-18 transfectants or in the serum of mice treated with Ad.PTH.IL-18 and/or rIL-12 was determined using ELISA (Pharmingen, San Diego, CA, USA, for IFN-␥ and Hayashibara Biochemical Institute, Okayama, Japan for IL-18, respectively) and is expressed as the amount from 10 6 of splenocytes or transfectants in 24 h. The IL-18 ELISA used here detects both the precursor and mature protein of IL-18. The lower limits of the detection of IFN-␥ and IL-18 by ELISA were 15.6 pg/ml.
Animal experiments and statistical evaluation C57/BL6 mice were purchased from Taconic Farms (Germantown, NY, USA) and were used for experiments when they were 7 to 10-weeks-old. All the animals were ear-tagged and randomized before the experiments and treated in a blinded fashion. 1 × 10 5 of MCA205 wild-type cells were inoculated i.d. in the flank of C57BL/6 mice on day 0. Each group consisted of five animals. Mice received daily i.p. injections of rIL-12 (a gift from Hoffman La-Roche Inc, Nutley, NJ, USA) or HBSS (GIBCO BRL, Grand Island, NY, USA) as a control. The tumor size was measured every 3-4 days and expressed as the product of the perpendicular diameters of individual tumors. Each animal experiment was repeated at least twice and representative results are shown. Blood samples from two mice per group were obtained by tail vein phlebotomy 1 day before and 2 days after adenovirus injection. Serum was separated by centrifugation and stored at −80°C until assayed. Nonparametric Wilcoxon rank test was used in the statistical analysis of the size of tumor and the number of immunostained cells infiltrated in tumor in individual groups. The difference was considered statistically significant when P value was less than 0.05.
Antibody depletion of immune cells
To deplete NK cells in mice, anti-ASGM1 antiserum (Wako Bioproducts, Richmond, VA, USA) was administered i.p. as previously described. 19 Monoclonal Abs against CD4
+ cells (GK1.5) and CD8 + cells (53-6.72) (all purchased from American Tissue Culture Collection, Rockville, MD, USA) were prepared and injected to mice to deplete subsets of immune cells 3 days before and once a week after the inoculation of tumor. These treatments are confirmed to deplete Ͼ95% of specific cell subsets in the spleen after the administration of Abs.
Immunohistological analysis
Mice received peritumoral injection of HBSS, 1 × 10 9 p.f.u. of AdLacZ or 1 × 10 9 p.f.u. of Ad.PTH.IL-18 7 days after the i.d. inoculation of 5 × 10 5 of MCA205 cells into the flank. Tumors were harvested 2 days after adenovirus injection. Tumors were immediately frozen and embedded in OCT compound. Serial 5-m sections were made from these tumors using cryostat and underwent immunochemical staining using Abs to CD4, CD8a, CD11b, CD11c, CD16 (all from Pharmingen, San Diego, CA, USA) and NLDC145 (Serotec, Oxford, UK) with the Vectastain ABC kit (Vector, Burlingame, CA, USA). The stained cells were counted in five fields at a magnification of ×400 in each sample. Evaluation of the results was performed in a blinded fashion.
